MX2020001644A - Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes. - Google Patents
Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes.Info
- Publication number
- MX2020001644A MX2020001644A MX2020001644A MX2020001644A MX2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A MX 2020001644 A MX2020001644 A MX 2020001644A
- Authority
- MX
- Mexico
- Prior art keywords
- senescent cells
- age
- conditions
- ophthalmic conditions
- glaucoma
- Prior art date
Links
- 206010012689 Diabetic retinopathy Diseases 0.000 title 1
- 208000010412 Glaucoma Diseases 0.000 title 1
- 208000002780 macular degeneration Diseases 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 230000007310 pathophysiology Effects 0.000 abstract 2
- 201000004569 Blindness Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940125381 senolytic agent Drugs 0.000 abstract 1
- 229940126586 small molecule drug Drugs 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/675,171 US20180000816A1 (en) | 2015-02-06 | 2017-08-11 | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US201762579793P | 2017-10-31 | 2017-10-31 | |
| PCT/US2018/046553 WO2019033119A1 (en) | 2017-08-11 | 2018-08-13 | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001644A true MX2020001644A (es) | 2020-07-13 |
Family
ID=63254539
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001644A MX2020001644A (es) | 2017-08-11 | 2018-08-13 | Tratamiento de afecciones oftalmicas tales como degeneracion macular, glaucoma y retinopatia diabetica usando agentes farmaceuticos que eliminan celulas senescentes. |
| MX2025004366A MX2025004366A (es) | 2017-08-11 | 2020-02-10 | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025004366A MX2025004366A (es) | 2017-08-11 | 2020-02-10 | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP3441069B1 (https=) |
| JP (2) | JP7278257B2 (https=) |
| CN (1) | CN111372598A (https=) |
| AU (2) | AU2018314280B2 (https=) |
| CA (1) | CA3072673A1 (https=) |
| MX (2) | MX2020001644A (https=) |
| WO (1) | WO2019033119A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| KR20240014102A (ko) | 2018-06-29 | 2024-01-31 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
| CA3109432A1 (en) * | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| JP2022548071A (ja) * | 2019-09-13 | 2022-11-16 | アメリカ合衆国 | 網膜変性を治療するための新薬の開発につながる標的 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| US20230078120A1 (en) * | 2020-05-04 | 2023-03-16 | Ascentage Pharma (Suzhou) Co.,Ltd. | Methods for Treating Coronavirus Infections |
| JP2024501033A (ja) * | 2020-12-28 | 2024-01-10 | エムディー ヘルスケア インコーポレイテッド | ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物 |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| JP2024516367A (ja) * | 2021-04-13 | 2024-04-15 | ユニティ バイオテクノロジー インコーポレイテッド | 網膜血管症を治療する方法 |
| KR102625248B1 (ko) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물 |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| DE112024002866T5 (de) * | 2023-07-06 | 2026-04-23 | Jichi Medical University | Konzentrationsregulator für In-vivo-Substanzen oder Medikamente in einem halbgeschlossenen In-vivo-System |
| CN119925379B (zh) * | 2025-03-05 | 2025-09-05 | 中南大学湘雅医院 | Bcl3抑制剂在制备治疗青光眼的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| BR0208856B1 (pt) | 2001-04-11 | 2013-02-05 | processo para o tratamento de superfÍcie de uma junta com rosca e junta com rosca para tubos de aÇo. | |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| WO2009094466A2 (en) | 2008-01-22 | 2009-07-30 | University Of Florida Research Foundation, Inc. | Contact lenses for extended release of bioactive agents containing diffusion attenuators |
| US8353856B2 (en) | 2008-11-05 | 2013-01-15 | Abbott Medical Optics Inc. | Glaucoma drainage shunts and methods of use |
| SG192126A1 (en) | 2011-01-25 | 2013-09-30 | Univ Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
| EP2922544B1 (en) | 2012-11-21 | 2018-08-01 | Eutropics Pharmaceuticals, Inc. | Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives |
| KR102318204B1 (ko) | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| CN105377289A (zh) * | 2013-04-21 | 2016-03-02 | 耶达研究及发展有限公司 | 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂 |
| US20150038140A1 (en) | 2013-07-31 | 2015-02-05 | Qualcomm Incorporated | Predictive mobility in cellular networks |
| WO2015017536A1 (en) | 2013-07-31 | 2015-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Method and system for evaluating progression of age-related macular degeneration |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| WO2017008060A1 (en) * | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
| US11111259B2 (en) * | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
-
2018
- 2018-08-13 EP EP18188799.3A patent/EP3441069B1/en active Active
- 2018-08-13 CA CA3072673A patent/CA3072673A1/en active Pending
- 2018-08-13 AU AU2018314280A patent/AU2018314280B2/en active Active
- 2018-08-13 EP EP23166363.4A patent/EP4234025A3/en active Pending
- 2018-08-13 JP JP2020507573A patent/JP7278257B2/ja active Active
- 2018-08-13 MX MX2020001644A patent/MX2020001644A/es unknown
- 2018-08-13 WO PCT/US2018/046553 patent/WO2019033119A1/en not_active Ceased
- 2018-08-13 CN CN201880063962.8A patent/CN111372598A/zh active Pending
-
2020
- 2020-02-10 MX MX2025004366A patent/MX2025004366A/es unknown
-
2023
- 2023-05-08 JP JP2023076763A patent/JP2023100864A/ja active Pending
- 2023-10-16 AU AU2023251388A patent/AU2023251388B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025004366A (es) | 2025-05-02 |
| EP3441069A1 (en) | 2019-02-13 |
| JP2023100864A (ja) | 2023-07-19 |
| WO2019033119A1 (en) | 2019-02-14 |
| AU2018314280B2 (en) | 2023-07-20 |
| AU2023251388A1 (en) | 2023-11-02 |
| CN111372598A (zh) | 2020-07-03 |
| AU2018314280A1 (en) | 2020-02-27 |
| EP4234025A3 (en) | 2024-04-24 |
| RU2020109987A (ru) | 2021-09-13 |
| JP2020530470A (ja) | 2020-10-22 |
| EP3441069B1 (en) | 2023-04-05 |
| JP7278257B2 (ja) | 2023-05-19 |
| EP4234025A2 (en) | 2023-08-30 |
| CA3072673A1 (en) | 2019-02-14 |
| AU2023251388B2 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025004366A (es) | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro | |
| Hamilos | Host-microbial interactions in patients with chronic rhinosinusitis | |
| Cuenca et al. | Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases | |
| SG11202104094YA (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| Elbaz et al. | Accelerated versus standard corneal collagen crosslinking combined with same day phototherapeutic keratectomy and single intrastromal ring segment implantation for keratoconus | |
| MX2022000754A (es) | Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal. | |
| EA201492031A1 (ru) | Способы лечения диабетической ретинопатии и других офтальмологических заболеваний | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| MX2011013060A (es) | Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. | |
| EA201990644A1 (ru) | Антисмысловые олигонуклеотиды для лечения глазного заболевания | |
| MX2016009331A (es) | Composiciones y metodos para tratar enfermedades oculares. | |
| WO2011139357A8 (en) | Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases | |
| MX361520B (es) | Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas. | |
| MX2021007709A (es) | Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. | |
| WO2011151685A8 (en) | N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament | |
| WO2011137344A3 (en) | Anti-s1p antibody treatment of patients with ocular disease | |
| Horner et al. | The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease | |
| NZ746468A (en) | Methods of treating ocular conditions | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| Mahadevan et al. | Unique hard scleral lens post-LASIK ectasia fitting | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| AR092842A1 (es) | Tratamiento de enfermedades inflamatorias oculares usando laquinimod |